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Table 2. Primary and secondary outcomes
Baseline Week 12 Change 95% CI
Responder (%)1 47 40 to 54
NRS pain (0-10) (SD) 6.7 (1) 5.3 (2) 1.4 (2) -1 to -2
NRS pain (0-10) (SD) 6.7 (1) 5.3 (2) 1.4 (2) -1 to -2
NRS PGA (0-10) (SD) 6.9 (2) 5.6 (2) 1.3 (2) -0.9 to -2
WOMAC-scores, mean (SD)2
pain 57 (19) 52 (23) -5.1 (19) -2 to -8
stiffness 62 (20) 58 (23) -3.8 (23) 0 to -8
function 58 (19) 52 (23) -5.6 (19) -3 to -8
1According to OMERACT-OARSI criteria; 2Scores are normalized (0-100; 0 = no symp-
toms). NRS, numeric rating scale;WOMAC-score,Western Ontario McMaster Universities
score; BMI, body mass index.
Results after 12 weeks are depicted in Table 2. OMERACT-OARSI responder
criteria were fulﬁlled in 47%; 39% reached NRS pain ≤4. In the univariate
analysis, NRS pain at baseline and low number of NSAIDs used for OA were
signiﬁcantly associated with an OMERACT-OARSI response, with only the
latter remaining as independent predictor for OMERACT-OARSI response
after 12 weeks in the multivariate analyses (OR 0.8, p = 0.03). No other
predictors were identiﬁed.
Conclusions: Basic ﬁrst-line recommended conservative treatment options
have not been adequately utilized prior to referral to secondary care in the
large majority of patients, but implementation is feasible and successful
in 47%. Furthermore, response was associated with (lack of) previous
conservative treatment.
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Purpose: Acetaminophen has been for decades recommended as a ﬁrst
line analgesic for osteoarthritis (OA) by consensus guidelines. However,
a recent update of the evidence led OARSI investigators to infer that
evidence for its eﬃcacy has diminished in strength. Furthermore, concerns
have also emerged in respect of its safety. We aimed to reassess the role
of acetaminophen, including the extended release formulation, in OA by
systematic review and latest evidence synthesis of studies reporting data
on its eﬃcacy and safety.
Methods: We searched Medline, EMBASE, CINAHL, BIOSIS, Google Scholar,
ISI Web of Science and Cochrane database from inception to April 2010.
We also hand searched review articles, manuscripts and supplements
from medical journals and contacted authors for unpublished data. We
included all human randomized clinical trials comparing acetaminophen
with placebo for OA. Two reviewers (RB, UD) independently performed
data extraction and assessed the quality of each trial. We computed effect
sizes for pain, function and stiffness (change from baseline) for each study
using Hedges’ g statistic corrected for small sample sizes. Effect sizes were
pooled using DerSimonian and Laird random effects model. Heterogeneity
was estimated with the help of I2 statistic. Sub group analyses were
undertaken for pain to determine whether the quality of trials inﬂuences
the results. Relative risk was calculated for any adverse event, GI events
and withdrawals due to adverse events.
Results: The 10 eligible trials included 3004 participants (acetaminophen
- 1515; placebo - 1489) with an age range of 56 to 70 years. They were
published between 1983 and 2007. Eight trials used immediate release
acetaminophen and two trials used extended release acetaminophen as an
active agent. The sample sizes varied between 25 and 779 with a mean of
300; 3 trials had a sample size less than 100. Trial duration ranged from 1 to
24 weeks. Allocation concealment was adequate in 4 trials. Intent-to-treat
analysis results were reported in 8 trials. Dropout rates ranged from 7 to
30% with 4 trials reporting >20%. Seven were industry sponsored trials and
one was sponsored by NIH.
For pain, we found a pooled effect size (ES) of 0.18 (95%CI 0.11, 0.25) favor-
ing acetaminophen with a heterogeneity score (I2) of 0% (Table 1A, Figure
1). For function, ES was 0.16 (95%CI 0.01, 0.31) favoring acetaminophen.
For stiffness, ES was 0.20 (95%CI 0.09, 0.32) favoring acetaminophen. The
sub group analyses showed no difference in eﬃcacy between different
formulations (Table 1B). However, safety analysis showed increase risk
in GI adverse events, more signiﬁcantly among the trials reporting liver
function tests (RR = 4.13 (2.11, 8.07) (Table 1C).
Table 1. Meta-analysis results
A. Pooled effect sizes (95% CI)
Trials N ES (95% CI) I2 (%)
Pain 9 2979 0.18 (0.11, 0.25) 0
Function 5 1915 0.16 (0.01, 0.31) 59
Stiffness 4 1218 0.20 (0.09, 0.32) 5
B. Sensitivity analyses for pain
Trials N ES (95% CI) I2 (%)
Immediate Release Acetaminophen 7 2112 0.17 (0.08, 0.25) 0
Extended Release Acetaminophen 2 867 0.21 (0.08, 0.35) 0
Intent-to-treat Analysis 8 2919 0.17 (0.10, 0.25) 0
Allocation Concealment 4 1247 0.25 (0.14, 0.36) 0
N > 100 7 2862 0.17 (0.10, 0.25) 0
C: Adverse events (Relative Risk)
Trials N RR (95% CI) I2 (%)
Any adverse events 9 2981 1.02 (0.93, 1.11) 0
Withdrawals due to adverse events 8 2683 1.21 (0.89, 1.65) 0
Any gastrointestinal adverse events 8 3373 1.40 (1.03, 1.89) 47
Increased hepatic enzyme levels 3 1079 4.13 (2.11, 8.07) 0
Figure 1. Forest plot.
Conclusions: This meta-analysis conﬁrms eﬃcacy of acetaminophen over
placebo, albeit at a low level barely reaching the minimal clinical thresh-
old. We also detected increase risk in GI adverse events with signiﬁcant
increases in liver enzymes. Therefore, acetaminophen as a short-term
analgesic in OA may still have utility, but with a questionable safety proﬁle.
Future randomized trials should include a longer duration of follow-up to
fully evaluate safety.
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Purpose: To assess the long-term ability of ASU to slow radiographic
progression in symptomatic hip OA
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Methods: Prospective, randomized, double-blind, parallel group, placebo-
controlled 3-year trial. Patients with primary hip OA (ACR criteria) were
randomly assigned to receive either 300 mg/day of ASU (n: 189) or placebo
(n: 209). Patients ≥ 45 years, symptomatic (painful ≥ 1 year, Lequesne
index ≥ 3) with a minimum joint space width (JSW) of the target hip
between 1-4 mm on a pelvic radiograph were randomized into 2 strata,
based on baseline JSW: < 2.5 or ≥ 2.5 mm. 3 standing radiographs
were taken annually: pelvis, target hip anteroposterior (AP), and oblique
views. JSW was measured at the narrowest point on pelvic or target hip
AP view by manual measurement using a 0.1 mm-graduated magnifying
glass. This method was deemed the most sensitive to change in a pilot
study and the best of 2 readers was selected prior to unblinding. The
primary outcome was based on the loss in the narrowest JSW over 3 years.
Statistics: All patients with at least 2 radiographs of the same view during
the trial were included in the Full Analysis dataSet (FAS) population. An
Analysis of Covariance Mixed Model for Repeated Measurements (MMRM)
was performed and Missing At Random (MAR) used to handle missing
data. Minimum adjusted JSW change was compared between groups by a
continuous approach: 3-year JS narrowing mean in mm and a more robust
analysis: comparison fo the percentage of "progressors" deﬁned by a JSW
loss ≥0.5 mm (based on the smallest detectable change of the reader [1]).
Results: 499 patients were selected, 399 randomized and 345 available
for the FAS (166 ASU; 179 placebo group). Baseline demographic and hip
OA characteristics were similar in both groups. Patients were aged 62 (8)
years, 54% were women, mean BMI was 27 (4), mean symptom duration 4
years (5), 0-100 normalised Lequesne index 30 (9), VAS global pain 37 (23)
mm. Mean baseline JSW was 2.8 (0.9) mm in both groups. 166 patients
discontinued the study, 55% of these for ineﬃcacy (74 were planned for
total joint replacement). Results of mean JSW loss and % of progressors at
year 3 are in Table 1.
Table 1. Results of the analysis on JS change
% Progressors Mean JS loss (sem)
Population ASU, Placebo, Cochrane Mantel Haenzel P ASU Placebo P
N=166 N=179 adjusted on stratus
Total 40% 50% 0.039 -0.64 (0.07) -0.67 (0.06) 0.72
sem: standard error of the mean.
Although no signiﬁcant intergroup difference was observed on the adjusted
mean JSW loss, the number of progressors was 20% lower in the ASU (p =
0.039). ASU were well tolerated in this study.
Conclusions: This study shows that 3-year treatment by ASU appears to
reduce the percentage of JSW deteriorating patients compared to placebo,
indicating a potential structure-modifying effect of ASU in hip OA. The
clinical relevance of these encouraging radiographic results requires further
assessment.
Reference
[1] Ornetti P. OAC 2009;17:842-9.
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Purpose: Prostaglandin E2 (PGE2) is one of the key mediators of inﬂam-
mation in rheumatoid arthritis (RA) joints. Intra-articular injection of high
molecular weight hyaluronan (HA) into RA knee joints relieves arthritic
pain. Although HA has been shown to inhibit PGE2 production in cytokine-
stimulated synovial ﬁbroblasts, it remains unclear how HA suppresses
PGE2 production in catabolically activated cells. Furthermore, HA effect on
macrophages has rarely been investigated in spite of their contribution
to RA joint pathology. This study was aimed to investigate the inhibitory
mechanism of HA on lipopolysaccharide (LPS)-stimulated PGE2 in U937
human macrophage culture system, which is a useful tool for experiments
on HA effect.
Methods: 1. U937 cells were treated with PMA for differentiation into
macrophages. With or without pretreatment with one of HA, NS-398, and
BAY11-7085, the cells were stimulated with LPS. In another set of exper-
iments, the cells were incubated with anti-CD44 antibody or non-speciﬁc
IgG before pretreatment with HA.
2. PGE2 concentrations of the cell-free supernatants were determined using
an enzyme-linked immunosorbent assay.
3. The cell lysates and nuclear extracts were prepared for immunoblot
analysis.
4. HA binding to CD44 was evaluated by ﬂuorescence microscopic analysis.
Results: Stimulation of U937 macrophages with LPS enhanced PGE2 pro-
duction in association with increased protein levels of cyclooxygenase-2
(COX-2). Pretreatment with HA of 2,700 kDa resulted in suppression of
LPS-induced COX-2, leading to a decrease in PGE2 production. While
LPS activated NF-κB pathway, inhibition studies revealed the requirement
of NF-κB for LPS-stimulated PGE2 production. HA down-regulated the
phosphorylation and nuclear translocation of NF-κB by LPS. Fluorescence
cytochemistry demonstrated that HA bound to CD44, the principal HA re-
ceptor, on U937 macrophages. Anti-CD44 antibody reversed the inhibitory
effects of HA on LPS-activated PGE2, COX-2, and NF-κB.
Conclusions: These results clearly demonstrated that HA of physiological
molecular weight suppressed LPS-stimulated PGE2 production via CD44
through down-regulation of NF-κB. Clinical administration of high molec-
ular weight HA into RA joints may decrease PGE2 production by activated
macrophages, which could result in improvement of arthritic pain.
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Purpose: Cyclooxygenase-inhibiting nitric oxide (NO) donators (CINOD) are
novel anti-inﬂammatory drugs in which NO donation is aimed at mitigating
the side effects of non steroidal anti-inﬂammatory drugs (NSAIDs). In
particular, naproxcinod, the ﬁrst-in-class CINOD, showed favorable effects
on systemic blood pressure, which is often elevated in elderly patients
suffering from osteoarthritis (OA) or rheumatoid arthritis (RA). The present
study was undertaken to assess the NO-mediated effects of NCX 429 in the
inﬂamed microvasculature.
Methods: Intravital microscopy (IVM) of the mouse mesentery was applied
to study ﬂuid (shear stress) and inﬂammatory (leukocyte adhesion) events
in male C57bl6 mice treated with L-NAME (2 mg/ml in the drinking water
for 5 days). NCX 429 (1.7-5.7-17 mg/kg) or naproxen (10 mg/kg, a dose
equivalent to the highest dose of NCX 429) was given orally 1 h prior
to 30 min observation of the microvasculature. The R-enantiomer of NCX
429 (NCX 1351, 5.7 mg/kg), which does not inhibit cyclooxygenase (COX)
but retains NO-donating properties, was also tested. In a separate set of
experiments, the effect of IL-1 beta treatment (10 ng, i.p.) on top of L-NAME
chronic exposure was tested, giving the cytokines 2 h prior to observation.
All data are mean ± SEM of 5 mice per group.
Results: Addition of L-NAME in the drinking water augmented shear stress
in the mesenteric post-capillary venules from ∼450 to 750 s-1 (p<0.05).
NCX 429 corrected this alteration at all doses tested. A similar effect was
observed on cell adhesion (data at 15 min): from 2.0±0.2 in control, to
4.8±0.3 and 2.1±0.1 adherent cells in L-NAME and L-NAME + NCX 429 (1.7
mg/kg), respectively (p<0.01). NCX 1351 was also effective on shear stress,
while naproxen altered neither shear stress nor cell adhesion. Addition of
IL-1 beta on top of L-NAME modiﬁed the microvascular status, bringing
shear stress back to control (untreated) values (475±20 s-1) and markedly
increasing cell adhesion (12.5±3.5 cells per post-capillary venule). Shear
stress was not affected by any of the pharmacological treatments. IL-1
beta-induced cell adhesion was effectively inhibited by NCX 429 even at
the lowest dose tested of 1.7 mg/kg (1.9±0.3 adherent cells; p<0.01 vs.
L-NAME + IL-1 beta), whereas naproxen only partially (∼50%) reduced cell
adhesion (7.0±0.7 cells per mouse; p<0.05 vs. L-NAME + IL-1 beta).
Conclusions: Removing endogenous production of NO alters microvascular
events in a way that is corrected by NCX 429. These effects, apparently
independent from COX inhibition, are particularly evident with respect
to shear stress (plausibly resulting from upstream vasoconstriction) and
cell adhesion (due to increased endothelial adhesiveness properties). Ad-
dition of IL-1 beta (inﬂammatory stimulus) on top of L-NAME unveiled
anti-inﬂammatory properties of naproxen, though NCX 429 was still more
potent and effective. Altogether these results widen our knowledge on the
properties of NCX 429 (and possibly other CINODs) and provide supporting
evidence for the favorable effects of CINODs on the vasculature.
